ON CLINICAL MILESTONE - CYTOMED THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ITS FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ALLOGENEIC CAR-GAMMA DELTA T CELL THERAPY IN PATIENTS WITH ADVANCED SOLID TUM ...

Fort Lauderdale, FL, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ("Algorhythm”) (NASDAQ: RIME) - an AI-driven technology and consumer electronics holding company, announced today its ...

Immunotherapies that use combination approaches are now emerging. Recent research from University College London demonstrated how engineered immune cells called gamma-delta T-cells could act as ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors. The company also began dosing a lupus nephritis patient ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Pan Am — the airline considered to be among the best of the world during travel’s so-called Golden Age — reportedly at one ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...

Here is a breakdown of the information In8bio, Inc. presented to its investors. IN8bio, Inc. is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell-based immunotherapies for ...

My doctor didn’t explain all the risks of my surgery, and I ended up with complications that I wasn’t prepared for. What can ...